About Gild
Gild: Revolutionizing the Biopharmaceutical Industry
Gilead Sciences, Inc. is a research-based biopharmaceutical company that has been at the forefront of developing innovative medicines for over three decades. Founded in 1987, Gilead has become a global leader in the biopharmaceutical industry with its focus on discovering and developing therapies for life-threatening diseases.
Gilead's mission is to improve the lives of patients suffering from serious illnesses by providing them with access to innovative treatments that address unmet medical needs. The company's portfolio includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases.
One of Gilead's most significant contributions to healthcare was its development of antiviral drugs that revolutionized the treatment of HIV/AIDS. In 1996, Gilead introduced Viread (tenofovir disoproxil fumarate), which became one of the most widely used antiretroviral drugs in HIV therapy. Since then, Gilead has continued to develop new therapies for HIV/AIDS and other infectious diseases.
In recent years, Gilead has expanded its focus beyond infectious diseases to include oncology and inflammation research areas. The company's oncology portfolio includes treatments for hematologic malignancies such as lymphoma and leukemia as well as solid tumors such as lung cancer.
Gild also focuses on developing therapies for inflammatory conditions such as rheumatoid arthritis (RA) and nonalcoholic steatohepatitis (NASH). RA is an autoimmune disease that causes chronic inflammation in joints leading to pain and stiffness while NASH is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by inflammation and damage to liver cells.
The success of Gild can be attributed not only to its commitment towards innovation but also towards collaboration with other organizations across academia, government agencies like FDA & EMA or NGOs like WHO & UNICEF. Gilead has established partnerships with leading academic institutions, research organizations, and biotech companies to advance its research and development efforts.
Gild's commitment to innovation is also reflected in its investment in cutting-edge technologies such as gene editing, cell therapy, and RNA interference (RNAi). These technologies have the potential to revolutionize the treatment of diseases by targeting specific genes or cells responsible for causing them.
In addition to its focus on developing innovative therapies, Gilead is also committed to ensuring that patients have access to these treatments. The company has implemented various programs such as patient assistance programs and pricing strategies that aim at making their products affordable for all patients regardless of their financial status.
Gild's commitment towards sustainability is evident from its efforts towards reducing carbon footprint through energy-efficient buildings & operations while also promoting diversity & inclusion across all levels of organization. The company has been recognized for its efforts towards sustainability by being included in Dow Jones Sustainability Index (DJSI) North America since 2016.
In conclusion, Gilead Sciences Inc., or Gild as it is commonly known, is a research-based biopharmaceutical company that has made significant contributions towards improving healthcare globally. Its focus on innovation coupled with collaboration with other organizations across academia & industry makes it one of the most respected names in the biopharmaceutical industry today. With a portfolio spanning infectious diseases like HIV/AIDS to oncology & inflammation areas like RA & NASH along with cutting-edge technologies like gene editing & cell therapy - Gild continues pushing boundaries while ensuring access for all patients through various affordability programs.